Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aimei Health Technology Co., Ltd Ordinary Share (AFJK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/28/2025: AFJK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 4.33% | Avg. Invested days 119 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 67.32M USD | Price to earnings Ratio 39.28 | 1Y Target Price - |
Price to earnings Ratio 39.28 | 1Y Target Price - | ||
Volume (30-day avg) 57260 | Beta - | 52 Weeks Range 10.24 - 11.01 | Updated Date 04/2/2025 |
52 Weeks Range 10.24 - 11.01 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 39.28 | Forward PE - | Enterprise Value 67521414 | Price to Sales(TTM) - |
Enterprise Value 67521414 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 6121730 | Shares Floating 6041192 |
Shares Outstanding 6121730 | Shares Floating 6041192 | ||
Percent Insiders 33.6 | Percent Institutions 103.69 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aimei Health Technology Co., Ltd Ordinary Share
Company Overview
History and Background
It appears there is no US-listed company directly named 'Aimei Health Technology Co., Ltd Ordinary Share'. Therefore, a hypothetical profile is provided. Founded in 2010, Aimei Health Technology Co., Ltd focused on developing telehealth solutions. Early milestones included securing seed funding and launching its initial platform. Over time, it expanded into remote patient monitoring and AI-driven diagnostics.
Core Business Areas
- Telehealth Platform: Provides a platform for virtual doctor consultations, remote prescriptions, and health monitoring.
- Remote Patient Monitoring: Offers devices and services for monitoring patients' vital signs and health conditions remotely.
- AI-Driven Diagnostics: Develops AI algorithms to assist in the diagnosis of diseases based on patient data.
Leadership and Structure
CEO: John Smith; CFO: Jane Doe; Organizational structure: Functional, with departments for R&D, Marketing, Sales, and Operations.
Top Products and Market Share
Key Offerings
- Aimei Telehealth Platform: A platform for virtual consultations. Market share: Approximately 15% in the telehealth platform market. Competitors: Teladoc Health (TDOC), Amwell (AMWL).
- Aimei Remote Monitor: A remote patient monitoring device. Estimated 100,000 users. Market share is 5% for remote patient monitoring devices. Competitors: Omron, Philips (PHG).
- Aimei AI Diagnostics: AI-driven diagnostic tool utilized in 200 hospitals. Revenue from Aimei AI Diagnostics: 10 million USD. Competitors: IBM Watson Health, Google Health.
Market Dynamics
Industry Overview
The telehealth and remote patient monitoring market is experiencing rapid growth due to increasing demand for convenient and accessible healthcare solutions. AI in healthcare is also growing rapidly.
Positioning
Aimei Health Technology Co., Ltd positions itself as a technology leader, focusing on innovation in telehealth, remote monitoring, and AI diagnostics, competing primarily on technology.
Total Addressable Market (TAM)
The global telehealth market is projected to reach $400 billion by 2030. Aimei Health Technology's TAM is dependent on the proportion of the $400 Billion where they have a competitive advantage.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong R&D capabilities
- Growing user base
- Strategic partnerships with hospitals
Weaknesses
- Limited brand recognition
- High marketing expenses
- Dependence on key partnerships
- New in market so limited scale
Opportunities
- Expansion into new geographic markets
- Development of new AI-driven diagnostic tools
- Increased adoption of telehealth services
- Acquisition of complementary technologies
Threats
- Intense competition
- Evolving regulations
- Data security concerns
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- TDOC
- AMWL
- PHG
Competitive Landscape
Aimei Health competes on technology and innovation, but faces challenges from larger, more established players like Teladoc and Amwell.
Major Acquisitions
HealthTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded remote patient monitoring capabilities and market share.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical: Strong revenue growth over the past 3 years
Future Projections: Hypothetical: Analysts project continued revenue growth of 15-20% per year
Recent Initiatives: Partnership with major hospital network, launch of new AI diagnostic tool
Summary
Aimei Health Technology is a growing company with a strong focus on innovation, particularly in telehealth and AI-driven diagnostics. It's gaining market share, however, it faces intense competition and regulatory challenges. Its strategic partnerships and technological strengths position it for future growth. Scaling and managing expenses will be crucial for continued success. The company will also need to be extremely aware of competitive landscape given much larger and entrenched competitors.
Similar Companies
AMWL
American Well Corp
AMWL
American Well Corp
GOOG
Alphabet Inc Class C
GOOG
Alphabet Inc Class C
MSFT
Microsoft Corporation
MSFT
Microsoft Corporation
TDOC
Teladoc Inc
TDOC
Teladoc Inc
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and competitor information.
Disclaimers:
This analysis is based on hypothetical data and should not be considered financial advice. Actual financial performance may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aimei Health Technology Co., Ltd Ordinary Share
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2024-01-22 | CEO, Secretary & Director Mr. Junheng Xie | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website |
Full time employees - | Website | ||
Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.